D-penicillamine and other low molecular weight thiols: Review of anticancer effects and related mechanisms

Cancer Letters

Volumn 337, Issue 1, 2013, Pages 8-21

  Wadhwa, Saurabh ^a   Mumper, Russell J ^b,c  

^a REGENERON PHARMACEUTICALS INC   (United States)

^b UNIVERSITY OF NORTH CAROLINA   (United States)

^c UNC Hamner Institute for Drug Safety Sciences   (United States)

Author keywords

Angiogenesis; Apoptosis; Free radical; Lipid peroxidation; P53

Indexed keywords

EID: 84880035767     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2013.05.027     Document Type: Review

References (213)

1. Sunitha K., Hemshekhar M., Thushara R.M., Sebastin M.S., Yeriswamy M., Kemparaju K., Girish K.S. N-acetylcysteine amide: a derivative to fulfill the promises of N-acetylcysteine. Free Radic. Res. 2013.
2. Vos O., Budke L., Vergroesen A.J. Protection of tissueculture cells against ionizing radiation. I. The effect of biological amines, disulphide compounds and thiols. Int. J. Radiat. Biol. 1962, 5:543-557.
3. Sprong R.C., Winkelhuyzen-Janssen A.M., Aarsman C.J., van Oirschot J.F., van der Bruggen T., van Asbeck B.S. Low-dose N-acetylcysteine protects rats against endotoxin-mediated oxidative stress, but high-dose increases mortality. Am. J. Respir. Crit. Care Med. 1998, 157:1283-1293.
4. Millea P.J. N-acetylcysteine: multiple clinical applications. Am. Fam. Physician 2009, 80:265-269.
5. Havre P.A., O'Reilly S., McCormick J.J., Brash D.E. Transformed and tumor-derived human cells exhibit preferential sensitivity to the thiol antioxidants. N-acetyl cysteine and penicillamine. Cancer Res. 2002, 62:1443-1449.
6. Molteni A., Ward W.F., Ts'ao C.H., Taylor J., Small W., Brizio-Molteni L., Veno P.A. Cytostatic properties of some angiotensin I converting enzyme inhibitors and of angiotensin II type I receptor antagonists. Curr. Pharm. Des. 2003, 9:751-761.
7. Held K.D., Biaglow J.E. Mechanisms for the oxygen radical-mediated toxicity of various thiol-containing compounds in cultured mammalian cells. Radiat. Res. 1994, 139:15-23.
8. Morse N.R., Tebbey P.W., Sandstrom P.A., Buttke T.M. Induction of apoptosis in lymphoid-cells by thiol-mediated oxidative stress. Protoplasma 1995, 184:181-187.
9. 2-catalyzed oxidation system. Arch. Biochem. Biophys. 1994, 312:285-291.
10. Searle A.J., Willson R.L. Stimulation of microsomal lipid peroxidation by iron and cysteine. Characterization and the role of free radicals. Biochem. J. 1983, 212:549-554.
11. Munday R. Toxicity of thiols and disulphides: involvement of free-radical species. Free Radic. Biol. Med. 1989, 7:659-673.
12. Zheng J., Lou J.R., Zhang X.X., Benbrook D.M., Hanigan M.H., Lind S.E., Ding W.Q. N-acetylcysteine interacts with copper to generate hydrogen peroxide and selectively induce cancer cell death. Cancer Lett. 2010, 298:186-194.
13. Munday R. Bioactivation of thiols by one-electron oxidation. Adv. Pharmacol. 1994, 27:237-270.
14. Albini A., D'Agostini F., Giunciuglio D., Paglieri I., Balansky R., De Flora S. Inhibition of invasion, gelatinase activity, tumor take and metastasis of malignant cells by N-acetylcysteine. Int. J. Cancer. J. Int du Cancer 1995, 61:121-129.
15. Albini A., Morini M., D'Agostini F., Ferrari N., Campelli F., Arena G., Noonan D.M., Pesce C., De Flora S. Inhibition of angiogenesis-driven Kaposi's sarcoma tumor growth in nude mice by oral N-acetylcysteine. Cancer Res. 2001, 61:8171-8178.
16. Lin J., Haffner M.C., Zhang Y., Lee B.H., Brennen W.N., Britton J., Kachhap S.K., Shim J.S., Liu J.O., Nelson W.G., Yegnasubramanian S., Carducci M.A. Disulfiram is a DNA demethylating agent and inhibits prostate cancer cell growth. Prostate 2011, 71:333-343.
17. Yakisich J.S., Siden A., Eneroth P., Cruz M. Disulfiram is a potent in vitro inhibitor of DNA topoisomerases. Biochem. Biophys. Res. Commun. 2001, 289:586-590.
18. Carpentieri U., Myers J., Thorpe L., Daeschner C.W., Haggard M.E. Copper, zinc, and iron in normal and leukemic lymphocytes from children. Cancer Res. 1986, 46:981-984.
19. Gupta S.K., Shukla V.K., Vaidya M.P., Roy S.K., Gupta S. Serum trace elements and Cu/Zn ratio in breast cancer patients. J. Surg. Oncol. 1991, 46:178-181.
20. Cohen Y., Epelbaum R., Haim N., McShan D., Zinder O. The value of serum copper levels in non-Hodgkin's lymphoma. Cancer 1984, 53:296-300.
21. Zuo X.L., Chen J.M., Zhou X., Li X.Z., Mei G.Y. Levels of selenium, zinc, copper, and antioxidant enzyme activity in patients with leukemia. Biol. Trace Elem. Res. 2006, 114:41-53.
22. Lightman A., Brandes J.M., Binur N., Drugan A., Zinder O. Use of the serum copper/zinc ratio in the differential diagnosis of ovarian malignancy. Clin. Chem. 1986, 32:101-103.
23. Yoshii J., Yoshiji H., Kuriyama S., Ikenaka Y., Noguchi R., Okuda H., Tsujinoue H., Nakatani T., Kishida H., Nakae D., Gomez D.E., De Lorenzo M.S., Tejera A.M., Fukui H. The copper-chelating agent, trientine, suppresses tumor development and angiogenesis in the murine hepatocellular carcinoma cells. Int. J. Cancer 2001, 94:768-773.
24. Pan Q., Kleer C.G., van Golen K.L., Irani J., Bottema K.M., Bias C., De Carvalho M., Mesri E.A., Robins D.M., Dick R.D., Brewer G.J., Merajver S.D. Copper deficiency induced by tetrathiomolybdate suppresses tumor growth and angiogenesis. Cancer Res. 2002, 62:4854-4859.
25. Brem S.S., Zagzag D., Tsanaclis A.M., Gately S., Elkouby M.P., Brien S.E. Inhibition of angiogenesis and tumor growth in the brain. Suppression of endothelial cell turnover by penicillamine and the depletion of copper, an angiogenic cofactor. Am. J. Pathol 1990, 137:1121-1142.
26. Malka F., Dairou J., Ragunathan N., Dupret J.M., Rodrigues-Lima F. Mechanisms and kinetics of human arylamine N-acetyltransferase 1 inhibition by disulfiram. FEBS J. 2009, 276:4900-4908.
27. Paranjpe A., Srivenugopal K.S. Degradation of NF-kappaB, p53 and other regulatory redox-sensitive proteins by thiol-conjugating and -nitrosylating drugs in human tumor cells. Carcinogenesis 2013, 34:990-1000.
28. Solovieva M.E., Solovyev V.V., Kudryavtsev A.A., Trizna Y.A., Akatov V.S. Vitamin B12b enhances the cytotoxicity of dithiothreitol. Free Radic. Biol. Med. 2008, 44:1846-1856.
29. Harada S., Sugiyama E., Taki H., Shinoda K., Fujita T., Maruyama M., Kobayashi M. D-penicillamine cooperates with copper sulfate to enhance the surface expression of functional Fas antigen in rheumatoid synovial fibroblasts via the generation of hydrogen peroxide. Clin. Exp. Rheum. 2002, 20:469-476.
30. Liu G.Y., Frank N., Bartsch H., Lin J.K. Induction of apoptosis by thiuramdisulfides, the reactive metabolites of dithiocarbamates, through coordinative modulation of NFkappaB, c-fos/c-jun, and p53 proteins. Mol. Carcinog. 1998, 22:235-246.
31. Gupte A., Mumper R.J. Copper chelation by D-penicillamine generates reactive oxygen species that are cytotoxic to human leukemia and breast cancer cells. Free Radic. Biol. Med. 2007, 43:1271-1278.
32. Gupte A., Mumper R.J. An investigation into copper catalyzed D-penicillamine oxidation and subsequent hydrogen peroxide generation. J. Inorg. Biochem. 2007, 101:594-602.
33. Winterbourn C.C., Metodiewa D. Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide. Free Radic. Biol. Med. 1999, 27:322-328.
34. Lipsky P.E., Ziff M. The effect of D-penicillamine on mitogen-induced human lymphocyte proliferation: synergistic inhibition by D-penicillamine and copper salts. J. Immunol. 1978, 120:1006-1013.
35. Trachootham D., Lu W., Ogasawara M.A., Nilsa R.D., Huang P. Redox regulation of cell survival. Antioxid. Redox Signal. 2008, 10:1343-1374.
36. Han D., Hanawa N., Saberi B., Kaplowitz N. Mechanisms of liver injury. III. Role of glutathione redox status in liver injury. Am. J. Physiol. Gastrointest. Liver Physiol. 2006, 291:G1-7.
37. Sobhakumari A., Love-Homan L., Fletcher E.V., Martin S.M., Parsons A.D., Spitz D.R., Knudson C.M., Simons A.L. Susceptibility of human head and neck cancer cells to combined inhibition of glutathione and thioredoxin metabolism. PLoS One 2012, 7:e48175.
38. Trapp V., Lee K., Doñate F., Mazar A.P., Fruehauf J.P. Redox-related antimelanoma activity of ATN-224. Melanoma Res. 2009, 19:350-360.
39. van Doorn R., Leijdekkers C.M., Henderson P.T. Synergistic effects of phorone on the hepatotoxicity of bromobenzene and paracetamol in mice. Toxicology 1978, 11:225-233.
40. Fruehauf J.P., Meyskens F.L. Reactive oxygen species: a breath of life or death?. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 2007, 13:789-794.
41. Lopez-Lazaro M. Dual role of hydrogen peroxide in cancer: possible relevance to cancer chemoprevention and therapy. Cancer Lett. 2007, 252:1-8.
42. Nicco C., Laurent A., Chereau C., Weill B., Batteux F. Differential modulation of normal and tumor cell proliferation by reactive oxygen species. Biomed. Pharm.=Biomed. Pharm. 2005, 59:169-174.
43. Lusini L., Tripodi S.A., Rossi R., Giannerini F., Giustarini D., del Vecchio M.T., Barbanti G., Cintorino M., Tosi P., Di Simplicio P. Altered glutathione anti-oxidant metabolism during tumor progression in human renal-cell carcinoma. Int. J. Cancer. J. Int. du Cancer 2001, 91:55-59.
44. Navarro J., Obrador E., Carretero J., Petschen I., Avino J., Perez P., Estrela J.M. Changes in glutathione status and the antioxidant system in blood and in cancer cells associate with tumour growth in vivo. Free Radic. Biol. Med. 1999, 26:410-418.
45. Pelicano H., Carney D., Huang P. ROS stress in cancer cells and therapeutic implications. Drug Resist. Updat.: Rev. Commentaries Antimicrob. Anticancer Chemother. 2004, 7:97-110.
46. Rhee S.G., Chae H.Z., Kim K. Peroxiredoxins: a historical overview and speculative preview of novel mechanisms and emerging concepts in cell signaling. Free Radic. Biol. Med. 2005, 38:1543-1552.
47. Rhee S.G., Woo H.A. Multiple functions of peroxiredoxins: peroxidases, sensors and regulators of the intracellular messenger H(2)O(2), and protein chaperones. Antioxid. Redox Signal. 2011, 15:781-794.
48. Chae H.Z., Kang S.W., Rhee S.G. Isoforms of mammalian peroxiredoxin that reduce peroxides in presence of thioredoxin. Methods Enzymol. 1999, 300:219-226.
49. Chae H.Z., Chung S.J., Rhee S.G. Thioredoxin-dependent peroxide reductase from yeast. J. Biol. Chem. 1994, 269:27670-27678.
50. Martin K.R., Barrett J.C. Reactive oxygen species as double-edged swords in cellular processes: low-dose cell signaling versus high-dose toxicity. Hum. Exp. Toxicol. 2002, 21:71-75.
51. Chandra J., Samali A., Orrenius S. Triggering and modulation of apoptosis by oxidative stress. Free Radic. Biol. Med. 2000, 29:323-333.
52. Gupte A., Mumper R.J. Elevated copper and oxidative stress in cancer cells as a target for cancer treatment. Cancer Treat. Rev. 2009, 35:32-46.
53. Liu M., Pelling J.C., Ju J., Chu E., Brash D.E. Antioxidant action via p53-mediated apoptosis. Cancer Res. 1998, 58:1723-1729.
54. Wondrak G.T., Jacobson M.K., Jacobson E.L. Antimelanoma activity of apoptogenic carbonyl scavengers. J. Pharmacol. Exp. Ther. 2006, 316:805-814.
55. G.T. Wondrak, M.K. Jacobson, E.L. Jacobson, Anti-melanoma activity of D-pencillamine and other carbonyl scavengers. In: Proc. Am. Assoc. Cancer Res., Orlando, FL, 2004, pp. 472-473.
56. Huber W.W., Parzefall W. Thiols and the chemoprevention of cancer. Curr. Opin. Pharmacol. 2007, 7:404-409.
57. Jay D., Cuella A., Jay E. Superoxide dismutase activity of the captopril-iron complex. Mol. Cell. Biochem. 1995, 146:45-47.
58. Roberts N.A., Robinson P.A. Copper chelates of antirheumatic and anti-inflammatory agents: their superoxide dismutase-like activity and stability. Br. J. Rheum. 1985, 24:128-136.
59. Searcy D.G. HS-:O2 oxidoreductase activity of Cu, Zn superoxide dismutase. Arch. Biochem. Biophys. 1996, 334:50-58.
60. Starkebaum G., Root R.K. D-penicillamine: analysis of the mechanism of copper-catalyzed hydrogen peroxide generation. J. Immunol. 1985, 134:3371-3378.
61. Kehrer J.P. The Haber-Weiss reaction and mechanisms of toxicity. Toxicology 2000, 149:43-50.
62. Held K.D., Sylvester F.C., Hopcia K.L., Biaglow J.E. Role of Fenton chemistry in thiol-induced toxicity and apoptosis. Radiat. Res. 1996, 145:542-553.
63. Rowley D.A., Halliwell B. Superoxide-dependent formation of hydroxyl radicals in the presence of thiol compounds. FEBS Lett. 1982, 138:33-36.
64. Issels R.D., Biaglow J.E., Epstein L., Gerweck L.E. Enhancement of cysteamine cytotoxicity by hyperthermia and its modification by catalase and superoxide dismutase in Chinese hamster ovary cells. Cancer Res. 1984, 44:3911-3915.
65. Winterbourn C.C., Hampton M.B. Thiol chemistry and specificity in redox signaling. Free Radic. Biol. Med. 2008, 45:549-561.
66. Sawada S., Okada S. Cysteamine, cystamine, and single-strand breaks of DNA in cultured mammalian cells. Radiat. Res. 1970, 44:116-132.
67. Lipsky P.E. Immunosuppression by D-penicillamine in vitro. Inhibition of human T lymphocyte proliferation by copper- or ceruloplasmin-dependent generation of hydrogen peroxide and protection by monocytes. J. Clin. Invest. 1984, 73:53-65.
68. Twomey P.J., Viljoen A., House I.M., Reynolds T.M., Wierzbicki A.S. Relationship between serum copper, ceruloplasmin, and non-ceruloplasmin-bound copper in routine clinical practice. Clin. Chem. 2005, 51:1558-1559.
69. Held K.D., Melder D.C. Toxicity of the sulfhydryl-containing radioprotector dithiothreitol. Radiat. Res. 1987, 112:544-554.
70. Takagi Y., Shikita M., Terasima T., Akaboshi S. Specificity of radioprotective and cytotoxic effects of cysteamine in HeLa S3 cells: generation of peroxide as the mechanism of paradoxical toxicity. Radiat. Res. 1974, 60:292-301.
71. Chaudiere J., Wilhelmsen E.C., Tappel A.L. Mechanism of selenium-glutathione peroxidase and its inhibition by mercaptocarboxylic acids and other mercaptans. J. Biol. Chem. 1984, 259:1043-1050.
72. Betts W.H., Cleland L.G., Gee D.J., Whitehouse M.W. Effects of D-penicillamine on a model of oxygen-derived free radical mediated tissue damage. Agents Actions 1984, 14:283-290.
73. Staite N.D., Messner R.P., Zoschke D.C. In vitro production and scavenging of hydrogen peroxide by D-penicillamine. Relationship to copper availability. Arth. Rheum. 1985, 28:914-921.
74. Yeung J.H. The effects of bucillamine on glutathione and glutathione-related enzymes in the mouse. Biochem. Pharmacol. 1991, 42:847-852.
75. Helliwell T.R., Yeung J.H., Park B.K. Hepatic necrosis and glutathione depletion in captopril-treated mice. Br. J. Exp. Pathol. 1985, 66:67-78.
76. Townsend D.M., Pazoles C.J., Tew K.D. NOV-002, a mimetic of glutathione disulfide. Expert Opin. Invest. Drugs 2008, 17:1075-1083.
77. Yamanaka H., Hakoda M., Kamatani N., Kashiwazaki S., Carson D.A. Formation of DNA strand breaks by D-penicillamine and bucillamine in human lymphocytes. ImmunoPharmacology 1993, 26:113-118.
78. Lipsky J.J., Shen M.L., Naylor S. In vivo inhibition of aldehyde dehydrogenase by disulfiram. Chem. Biol. Interact. 2001, 130-132:93-102.
79. Wallace S.S. The biological consequences of oxidized DNA bases. Br. J. Cancer Supplement 1987, 8:118-128.
80. Breen A.P., Murphy J.A. Reactions of oxyl radicals with DNA. Free Radic. Biol. Med. 1995, 18:1033-1077.
81. Dulger S., Saglam N., Belduz A.O., Guner S., Karabocek S. DNA cleavage by homo- and heterotetranuclear Cu(II) and Mn(II) complexes with tetrathioether-tetrathiol moiety. Biometals: An Int. J. Role Metal Ions Biol., Biochem. Med. 2000, 13:261-265.
82. Bertram C., Hass R. Cellular responses to reactive oxygen species-induced DNA damage and aging. Biol. Chem. 2008, 389:211-220.
83. Ribizzi I., Darnowski J.W., Goulette F.A., Sertoli M.R., Calabresi P. Amifostine cytotoxicity and induction of apoptosis in a human myelodysplastic cell line. Leukemia Res. 2000, 24:519-525.
84. Lynn S., Yu G.L., Yan K. Vicinal-thiol-containing molecules enhance but mono-thiol-containing molecules reduce nickel-induced DNA strand breaks. Toxicol. Appl. Pharmacol. 1999, 160:198-205.
85. Tien M., Bucher J.R., Aust S.D. Thiol-dependent lipid peroxidation. Biochem. Biophys. Res. Commun. 1982, 107:279-285.
86. Schoneich C., Dillinger U., von Bruchhausen F., Asmus K.D. Oxidation of polyunsaturated fatty acids and lipids through thiyl and sulfonyl radicals: reaction kinetics, and influence of oxygen and structure of thiyl radicals. Arch. Biochem. Biophys. 1992, 292:456-467.
87. Cejas P., Casado E., Belda-Iniesta C., De Castro J., Espinosa E., Redondo A., Sereno M., Garcia-Cabezas M.A., Vara J.A., Dominguez-Caceres A., Perona R., Gonzalez-Baron M. Implications of oxidative stress and cell membrane lipid peroxidation in human cancer (Spain). Cancer Causes Control: CCC 2004, 15:707-719.
88. Ferreri C., Costantino C., Landi L., Mulazzani Q.G., Chatgilialoglu C. The thiyl radical-mediated isomerization of cis-monounsaturated fatty acid residues in phospholipids: a novel path of membrane damage?. Chem. Commun. 1999, 407-408.
89. Borisenko G.G., Martin I., Zhao Q., Amoscato A.A., Tyurina Y.Y., Kagan V.E. Glutathione propagates oxidative stress triggered by myeloperoxidase in HL-60 cells. Evidence for glutathionyl radical-induced peroxidation of phospholipids and cytotoxicity. J. Biol. Chem. 2004, 279:23453-23462.
90. Held K.D., Tuttle S.W., Biaglow J.E. Role of the pentose cycle in oxygen radical-mediated toxicity of the thiol-containing radioprotector dithiothreitol in mammalian cells. Radiat. Res. 1993, 134:383-389.
91. Stridh H., Kimland M., Jones D.P., Orrenius S., Hampton M.B. Cytochrome c release and caspase activation in hydrogen peroxide- and tributyltin-induced apoptosis. FEBS Lett. 1998, 429:351-355.
92. Chen S.H., Lin J.K., Liang Y.C., Pan M.H., Liu S.H., Lin-Shiau S.Y. Involvement of activating transcription factors JNK, NF-kappaB, and AP-1 in apoptosis induced by pyrrolidine dithiocarbamate/Cu complex. Eur. J. Pharmacol. 2008, 594:9-17.
93. Johans M., Milanesi E., Franck M., Johans C., Liobikas J., Panagiotaki M., Greci L., Principato G., Kinnunen P.K., Bernardi P., Costantini P., Eriksson O. Modification of permeability transition pore arginine(s) by phenylglyoxal derivatives in isolated mitochondria and mammalian cells. Structure-function relationship of arginine ligands. J. Biol. Chem. 2005, 280:12130-12136.
94. Sakamoto H., Mashima T., Yamamoto K., Tsuruo T. Modulation of heat-shock protein 27 (Hsp27) anti-apoptotic activity by methylglyoxal modification. J. Biol. Chem. 2002, 277:45770-45775.
95. Liu B., Chen Y., St Clair D.K. ROS and p53: a versatile partnership. Free Radic. Biol. Med. 2008, 44:1529-1535.
96. Zhao Y., Seefeldt T., Chen W., Carlson L., Stoebner A., Hanson S., Foll R., Matthees D.P., Palakurthi S., Guan X. Increase in thiol oxidative stress via glutathione reductase inhibition as a novel approach to enhance cancer sensitivity to X-ray irradiation. Free Radic. Biol. Med. 2009, 47:176-183.
97. Sablina A.A., Budanov A.V., Ilyinskaya G.V., Agapova L.S., Kravchenko J.E., Chumakov P.M. The antioxidant function of the p53 tumor suppressor. Nat. Med. 2005, 11:1306-1313.
98. Polyak K., Xia Y., Zweier J.L., Kinzler K.W., Vogelstein B. A model for p53-induced apoptosis. Nature 1997, 389:300-305.
99. Hainaut P., Mann K. Zinc binding and redox control of p53 structure and function. Antiox. Redox Signal. 2001, 3:611-623.
100. Abbas T., Dutta A. P21 in cancer: intricate networks and multiple activities. Nat. Rev. Cancer 2009, 9:400-414.
101. Chinery R., Brockman J.A., Peeler M.O., Shyr Y., Beauchamp R.D., Coffey R.J. Antioxidants enhance the cytotoxicity of chemotherapeutic agents in colorectal cancer: a p53-independent induction of p21WAF1/CIP1 via C/EBPbeta. Nat. Med. 1997, 3:1233-1241.
102. Bennett M., Macdonald K., Chan S.W., Luzio J.P., Simari R., Weissberg P. Cell surface trafficking of Fas: a rapid mechanism of p53-mediated apoptosis. Science 1998, 282:290-293.
103. Mahmood Z., Shukla Y. Death receptors: targets for cancer therapy. Exp. Cell Res. 2010, 316:887-899.
104. Guan D., Xu Y., Yang M., Wang H., Wang X., Shen Z. N-acetyl cysteine and penicillamine induce apoptosis via the ER stress response-signaling pathway. Mol. Carcinog. 2010, 49:68-74.
105. Tartier L., McCarey Y.L., Biaglow J.E., Kochevar I.E., Held K.D. Apoptosis induced by dithiothreitol in HL-60 cells shows early activation of caspase 3 and is independent of mitochondria. Cell Death Differ. 2000, 7:1002-1010.
106. Friteau L., Jaffray P., Ronot X., Adolphe M. Differential effect of D-penicillamine on the cell kinetic parameters of various normal and transformed cellular types. J. Cell. Physiol. 1988, 136:514-518.
107. Jeitner T.M., Delikatny E.J., Bartier W.A., Capper H.R., Hunt N.H. Inhibition of drug-naive and -resistant leukemia cell proliferation by low molecular weight thiols. Biochem. Pharmacol. 1998, 55:793-802.
108. Menon S.G., Sarsour E.H., Kalen A.L., Venkataraman S., Hitchler M.J., Domann F.E., Oberley L.W., Goswami P.C. Superoxide signaling mediates N-acetyl-L-cysteine-induced G1 arrest: regulatory role of cyclin D1 and manganese superoxide dismutase. Cancer Res. 2007, 67:6392-6399.
109. Menon S.G., Sarsour E.H., Spitz D.R., Higashikubo R., Sturm M., Zhang H., Goswami P.C. Redox regulation of the G1 to S phase transition in the mouse embryo fibroblast cell cycle. Cancer Res. 2003, 63:2109-2117.
110. Folkman J. Tumor angiogenesis: therapeutic implications. New Engl. J. Med. 1971, 285:1182-1186.
111. Matsubara T., Saura R., Hirohata K., Ziff M. Inhibition of human endothelial cell proliferation in vitro and neovascularization in vivo by D-penicillamine. J. Clin. Invest. 1989, 83:158-167.
112. Elner S.G., Elner V.M., Yoshida A., Dick R.D., Brewer G.J. Effects of tetrathiomolybdate in a mouse model of retinal neovascularization. Invest. Ophthalmol. Vis. Sci. 2005, 46:299-303.
113. Brem S., Grossman S.A., Carson K.A., New P., Phuphanich S., Alavi J.B., Mikkelsen T., Fisher J.D. New Approaches Brain Tumor, Phase 2 trial of copper depletion and penicillamine as antiangiogenesis therapy of glioblastoma. Neuro-Oncology 2005, 7:246-253.
114. O'Reilly M.S., Holmgren L., Shing Y., Chen C., Rosenthal R.A., Moses M., Lane W.S., Cao Y., Sage E.H., Folkman J. Angiostatin: a novel angiogenesis inhibitor that mediates the suppression of metastases by a Lewis lung carcinoma. Cell 1994, 79:315-328.
115. Gately S., Twardowski P., Stack M.S., Cundiff D.L., Grella D., Castellino F.J., Enghild J., Kwaan H.C., Lee F., Kramer R.A., Volpert O., Bouck N., Soff G.A. The mechanism of cancer-mediated conversion of plasminogen to the angiogenesis inhibitor angiostatin. Proc. Nat. Acad. Sci. USA 1997, 94:10868-10872.
116. de Groot-Besseling R.R.J., Ruers T.J.M., Lamers-Elemans I.L., Maass C.N., de Waal R.M.W., Westphal J.R. Angiostatin generating capacity and anti-tumour effects of D-penicillamine and plasminogen activators. Bmc Cancer 2006, 6.
117. Gialeli C., Theocharis A.D., Karamanos N.K. Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. FEBS J. 2011, 278:16-27.
118. Duffy M.J. The role of proteolytic enzymes in cancer invasion and metastasis. Clin. Exp. Metastasis 1992, 10:145-155.
119. Liotta L.A., Tryggvason K., Garbisa S., Hart I., Foltz C.M., Shafie S. Metastatic potential correlates with enzymatic degradation of basement membrane collagen. Nature 1980, 284:67-68.
120. Egeblad M., Werb Z. New functions for the matrix metalloproteinases in cancer progression. Nat. Rev. Cancer 2002, 2:161-174.
121. Pavlaki M., Zucker S. Matrix metalloproteinase inhibitors (MMPIs): the beginning of phase I or the termination of phase III clinical trials. Cancer Metastasis Rev. 2003, 22:177-203.
122. Rundhaug J.E. Matrix metalloproteinases, angiogenesis, and cancer: commentary re: A.C. Lockhart et al., Reduction of wound angiogenesis in patients treated with BMS-275291, a broad spectrum matrix metalloproteinase inhibitor. Clin. Cancer Res. 2003, 9:551-554.
123. Noe V., Fingleton B., Jacobs K., Crawford H.C., Vermeulen S., Steelant W., Bruyneel E., Matrisian L.M., Mareel M. Release of an invasion promoter E-cadherin fragment by matrilysin and stromelysin-1. J. Cell Sci. 2001, 114:111-118.
124. Huang J., Gao F., Tang X.X., Yu J.H., Wang D.X., Liu S.Y., Li Y.P. Liver-targeting doxorubicin-conjugated polymeric prodrug with pH-triggered drug release profile. Polym. Int. 2010, 59:1390-1396.
125. Volpert O.V., Ward W.F., Lingen M.W., Chesler L., Solt D.B., Johnson M.D., Molteni A., Polverini P.J., Bouck N.P. Captopril inhibits angiogenesis and slows the growth of experimental tumors in rats. J. Clin. Invest. 1996, 98:671-679.
126. Siegel R.C. Collagen cross-linking. Effect of D-penicillamine on cross-linking in vitro. J. Biol. Chem. 1977, 252:254-259.
127. Nimni M.E. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. I. Metabolic and functional abnormalities in soft tissues. J. Biol. Chem. 1968, 243:1457-1466.
128. Deshmukh K., Just M., Nimni M.E. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. 3. Accumulation of acid soluble collagen with a high hydroxylysine content in bone. Clin. Orthop. Relat. Res. 1973, 186-196.
129. Deshmukh K., Nimni M.E. A defect in the intramolecular and intermolecular cross-linking of collagen caused by penicillamine. II. Functional groups involved in the interaction process. J. Biol. Chem. 1969, 244:1787-1795.
130. Nimni M.E., Deshmukh K., Gerth N. Collagen defect induced by penicillamine. Nat. New Biol. 1972, 240:220-221.
131. Rucker R.B., Kosonen T., Clegg M.S., Mitchell A.E., Rucker B.R., Uriu-Hare J.Y., Keen C.L. Copper, lysyl oxidase, and extracellular matrix protein cross-linking. Am. J. Clin. Nutr. 1998, 67:996S-1002S.
132. Chvapil M. Inhibition of breast adenocarcinoma growth by intratumoral injection of lipophilic long-acting lathyrogens. Anticancer Drugs 2005, 16:201-210.
133. Chvapil M., Dorr R. Single intratumoral injection of long-acting benzyl ester of D-penicillamine inhibits the growth of melanoma tumor in mice. Anticancer Drugs 2005, 16:757-762.
134. Chvapil M., Kielar F., Liska F., Silhankova A., Brendel K. Synthesis and evaluation of long-acting D-penicillamine derivatives. Conn. Tissue Res. 2005, 46:242-250.
135. Ward J.R. Role of disease-modifying antirheumatic drugs versus cytotoxic agents in the therapy of rheumatoid arthritis. Am. J. Med. 1988, 85:39-44.
136. Gerber D.A. Inhibition of the denaturation of human gamma globulin by a mixture of D-penicillamine disulfide and copper. A possible mechanism of action of D-penicillamine in rheumatoid arthritis. Biochem. Pharmacol. 1978, 27:469-472.
137. Samoszuk M., Nguyen V. In vitro and in vivo interactions of D-penicillamine with tumors. Anticancer Res. 1996, 16:1219-1223.
138. Baier-Bitterlich G., Schumacher W., Schulz T.F., Wachter H., Dierich M.P. Effects of D-penicillamine on human cell lines. Arzneimittelforschung 1993, 43:395-398.
139. Aposhian H.V., Bradham L.S. Metabolism in vitro of the sulphydryl amino acids, L- and D-penicillamine. Biochem. Pharmacol. 1959, 3:38-41.
140. Lodemann E. Transport of D- and L-penicillamine by mammalian cells. Biochem. Biophys. Res. Commun. 1981, 102:775-783.
141. Schumacher K., Maerker-Alzer G., Preuss R. Effect of D-penicillamine on lymphocyte function. Arzneimittelforschung 1975, 25:603-606.
142. Joyce D.A., Day R.O., Murphy B.R. The pharmacokinetics of albumin conjugates of D-penicillamine in humans. Drug Metab. Disp.: Biol. Fate Chem. 1991, 19:309-311.
143. Joyce D.A., Wade D.N., Swanson B.R. The pharmacokinetics of albumin conjugates of D-penicillamine in rats. Drug Metab. Disp.: Biol. Fate Chem. 1989, 17:208-211.
144. Planas-Bohne F. Metabolism and pharmacokinetics of penicillamine in rats - an overview. J. Rheumatol. Suppl. 1981, 7:35-40.
145. Gupte A., Wadhwa S., Mumper R.J. Enhanced intracellular delivery of the reactive oxygen species (ROS)-generating copper chelator D-penicillamine via a novel gelatin-D-penicillamine conjugate. Bioconjug. Chem. 2008, 19:1382-1388.
146. Wadhwa S., Mumper R.J. Intracellular delivery of the reactive oxygen species generating agent D-penicillamine upon conjugation to poly-l-glutamic acid. Mol. Pharm. 2010, 7:854-862.
147. Cai T., Fassina G., Morini M., Aluigi M.G., Masiello L., Fontanini G., D'Agostini F., De Flora S., Noonan D.M., Albini A. N-acetylcysteine inhibits endothelial cell invasion and angiogenesis. Lab. Invest.; J. Tech. Methods Pathol. 1999, 79:1151-1159.
148. De Flora S., D'Agostini F., Masiello L., Giunciuglio D., Albini A. Synergism between N-acetylcysteine and doxorubicin in the prevention of tumorigenicity and metastasis in murine models. Int. J. Cancer 1996, 67:842-848.
149. Leggio L., Addolorato G., Abenavoli L., Gasbarrini G. Wilson's disease: clinical, genetic and pharmacological findings. Int. J. Immunopathol. Pharmacol. 2005, 18:7-14.
150. Henry N.L., Dunn R., Merjaver S., Pan Q., Pienta K.J., Brewer G., Smith D.C. Phase II trial of copper depletion with tetrathiomolybdate as an antiangiogenesis strategy in patients with hormone-refractory prostate cancer. Oncology 2006, 71:168-175.
151. Pass H.I., Brewer G.J., Dick R., Carbone M., Merajver S. A phase II trial of tetrathiomolybdate after surgery for malignant mesothelioma: final results. Ann. Thoracic Surgery 2008, 86:383-389. discussion 390.
152. Redman B.G., Esper P., Pan Q., Dunn R.L., Hussain H.K., Chenevert T., Brewer G.J., Merajver S.D. Phase II trial of tetrathiomolybdate in patients with advanced kidney cancer. Clin. Cancer Res. 2003, 9:1666-1672.
153. Pan Q., Rosenthal D.T., Bao L., Kleer C.G., Merajver S.D. Antiangiogenic tetrathiomolybdate protects against Her2/neu-induced breast carcinoma by hypoplastic remodeling of the mammary gland. Clin. Cancer Res.: An Off. J. Am. Assoc. Cancer Res. 2009, 15:7441-7446.
154. Cox C., Merajver S.D., Yoo S., Dick R.D., Brewer G.J., Lee J.S., Teknos T.N. Inhibition of the growth of squamous cell carcinoma by tetrathiomolybdate-induced copper suppression in a murine model. Arch. Otolaryngol. - Head Neck Surg. 2003, 129:781-785.
155. Cox C., Teknos T.N., Barrios M., Brewer G.J., Dick R.D., Merajver S.D. The role of copper suppression as an antiangiogenic strategy in head and neck squamous cell carcinoma. Laryngoscope 2001, 111:696-701.
156. Brewer G.J., Dick R.D., Grover D.K., LeClaire V., Tseng M., Wicha M., Pienta K., Redman B.G., Jahan T., Sondak V.K., Strawderman M., LeCarpentier G., Merajver S.D. Treatment of metastatic cancer with tetrathiomolybdate, an anticopper, antiangiogenic agent: phase I study. Clin. Cancer Res. 2000, 6:1-10.
157. Khan M.K., Mamou F., Schipper M.J., May K.S., Kwitny A., Warnat A., Bolton B., Nair B.M., Kariapper M.S., Miller M., Brewer G., Normolle D., Merajver S.D., Teknos T.N. Combination tetrathiomolybdate and radiation therapy in a mouse model of head and neck squamous cell carcinoma. Arch. Otolaryngol. - Head Neck Surg. 2006, 132:333-338.
158. Townsend D.M., Tew K.D. Pharmacology of a mimetic of glutathione disulfide, NOV-002. Biomed. Pharm. 2009, 63:75-78.
159. Brennan J.P., Miller J.I., Fuller W., Wait R., Begum S., Dunn M.J., Eaton P. The utility of N, N-biotinyl glutathione disulfide in the study of protein S-glutathiolation. Mol. Cell. Proteomics: MCP 2006, 5:215-225.
160. Jenderny S., Lin H., Garrett T., Tew K.D., Townsend D.M. Protective effects of a glutathione disulfide mimetic (NOV-002) against cisplatin induced kidney toxicity. Biomed. Pharma.=Biomed. Pharm. 2010, 64:73-76.
161. C.J. Pazoles, H. Gernstein, NOV-002, a chemoprotectant/immunomodulator, added to first-ine carboplatin/paclitaxel in advanced non-small cell lung cancer (NSCLC): a randomized phase 1/2, open-label, controlled study, in: 2006 ASCO Annual Meeting Proceedings Part I, 2006, pp. 17021.
162. P. Fidias, T.A. Ciuleanu, O. Gladkov, G.M. Manikhas, I.N. Bondarenko, A. Pluzanska, R. Ramlau, T.J. Lynch, A randomized, open-label, phase III trial of NOV-002 in combination with paclitaxel (P) and carboplatin (C) versus paclitaxel and carboplatin alone for the treatment of advanced non-small cell lung cancer (NSCLC), in: 2010 ASCO Annual Meeting Proceedings, 2010, pp. LBA7007.
163. Burkert H., Schnitker J., Fichtner E. Prevention of urinary tract toxicity of oxazaphosphorines by a "uroprotector". Report on a field study (author's transl). MMW Munch Med. Wochenschr. 1979, 121:760-762.
164. Aksoy S., Hizli D., Sarici S., Ocalan R., Kose M.F., Guler N. A retrospective review of metastatic or recurrent uterine sarcomas treated with ifosfamide and doxorubicin (IMA). UHOD, Uluslararasi Hematol.-Onkol. Derg. 2008, 18:129-134.
165. Baur M., Fazeny-Doerner B., Hudec M., Sevelda P., Salzer H., Dittrich C. Ifosfamide/Mesna as salvage therapy in platinum pretreated ovarian cancer patients-long-term results of a phase II study. Cancer Invest. 2006, 24:22-27.
166. Walters R.S., Holmes F.A., Valero V., Esparza-Guerra L., Hortobagyi G.N. Phase II study of ifosfamide and mesna in patients with metastatic breast cancer. Am. J. Clin. Oncol. 1998, 21:413-415.
167. Blomgren H., Hallstroem M., Hillgren H. Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Its potential use in the treatment of superficial bladder cancer. Anticancer Res. 1991, 11:773-776.
168. Blomgren H., Hallstroem M., Hillgren H. Antitumor activity of 2-mercaptoethanesulfonate (mesna) in vitro. Methods Find. Exp. Clin. Pharmacol. 1990, 12:691-697.
169. Shaw I.C., Weeks M.S. Interaction between mesna and selected transition metals in vitro and in vivo. Arzneim.-Forsch. 1986, 36:997-1000.
170. Soff G.A., Wang H., Cundiff D.L., Jiang K., Martone B., Rademaker A.W., Doll J.A., Kuzel T.M. In vivo generation of angiostatin isoforms by administration of a plasminogen activator and a free sulfhydryl donor: a phase I study of an angiostatic cocktail of tissue plasminogen activator and mesna. Clin. Cancer Res. 2005, 11:6218-6225.
171. Yuhas J.M. Improvement of lung tumor radiotherapy through differential chemoprotection of normal and tumor tissue. J. Nat. Cancer Inst. 1972, 48:1255-1257.
172. Yuhas J.M. Differential protection of normal and malignant tissues against the cytotoxic effects of mechlorethamine. Cancer Treat. Rep. 1979, 63:971-976.
173. Yuhas J.M., Storer J.B. Differential chemoprotection of normal and malignant tissues. J. Nat. Cancer Inst. 1969, 42:331-335.
174. Treskes M., Nijtmans L., Fichtinger-Schepman A.M.J., Van D.V.W.J.F. Cytostatic activity of cisplatin in the presence of WR2721 and its thiol metabolite WR1065 in OVCAR-3 human ovarian cancer cells as compared to V79 fibroblasts. Anticancer Res. 1992, 12:2261-2265.
175. Milas L., Hunter N., Ito H., Peters L.J. Effect of tumor type, size, and endpoint on tumor radioprotection by WR-2721. Int. J. Radiat. Oncol., Biol., Phys. 1984, 10:41-48.
176. L. Milas, N. Hunter, H. Ito, E.L. Travis, L.J. Peters, Factors influencing radioprotection of tumors by WR-2721, in: Academic, 1983, pp. 695-718.
177. Ikebuchi M., Shinohara S., Kimura H., Morimoto K., Shima A., Aoyama T. Effects of daily treatment with a radioprotector WR-2721 on Ehrlich's ascites tumors in mice: suppression of tumor cell growth and earlier death of tumor-bearing mice. J. Radiat. Res. 1981, 22:258-264.
178. Schor N.F.T. Adjunctive use of ethiofos (WR-2721) with free radical-generating chemotherapeutic agents in mice: new caveats for therapy. Cancer Res. 1987, 47:5411-5414.
179. Yuhas J.M., Davis M.E., Glover D., Brown D.Q., Ritter M. Circumvention of the tumor membrane barrier to WR-2721 absorption by reduction of drug hydrophilicity. Int. J. Radiat. Oncol., Biol. Phys. 1982, 8:519-522.
180. Issels R.D., Nagele A. Promotion of cystine uptake, increase of glutathione biosynthesis, and modulation of glutathione status by S-2-(3-aminopropylamino)ethyl phosphorothioic acid (WR-2721) in Chinese hamster cells. Cancer Res. 1989, 49:2082-2086.
181. North S., El-Ghissassi F., Pluquet O., Verhaegh G., Hainaut P. The cytoprotective aminothiol WR1065 activates p21waf-1 and down regulates cell cycle progression through a p53-dependent pathway. Oncogene 2000, 19:1206-1214.
182. Swisher S.G., Pataer A., Yu R., Nishizaki M., Fang B., Hunt K.K., Roth J.A. Enhancement of adenoviral-mediated p53 tumor killing with amifostine-induced CDC2 kinase activation. Surg. Forum 2000, 51:312-313.
183. Pataer A., Fanale M.A., Roth J.A., Swisher S.G., Hunt K.K. Induction of apoptosis in human lung cancer cells following treatment with amifostine and an adenoviral vector containing wild-type p53. Cancer Gene Ther. 2006, 13:806-814.
184. Giannopoulou E., Katsoris P., Kardamakis D., Papadimitriou E. Amifostine inhibits angiogenesis in vivo. J. Pharmacol. Exp. Ther. 2003, 304:729-737.
185. Grdina D.J., Kataoka Y., Murley J.S., Hunter N., Weichselbaum R.R., Milas L. Inhibition of spontaneous metastases formation by amifostine. Int. J. Cancer. J. Int. du Cancer 2002, 97:135-141.
186. Wilop S., von Hobe S., Crysandt M., Esser A., Osieka R., Jost E. Impact of angiotensin I converting enzyme inhibitors and angiotensin II type 1 receptor blockers on survival in patients with advanced non-small-cell lung cancer undergoing first-line platinum-based chemotherapy. J. Cancer Res. Clin. Oncol. 2009, 135:1429-1435.
187. Fernandez L.A., Twickler J., Mead A. Neovascularization produced by angiotensin II. J. Lab. Clin. Med. 1985, 105:141-145.
188. Le Noble F.A., Schreurs N.H., van Straaten H.W., Slaaf D.W., Smits J.F., Rogg H., Struijker-Boudier H.A. Evidence for a novel angiotensin II receptor involved in angiogenesis in chick embryo chorioallantoic membrane. Am. J. Physiol. 1993, 264:R460-465.
189. Sorbi D., Fadly M., Hicks R., Alexander S., Arbeit L. Captopril inhibits the 72kDa and 92kDa matrix metalloproteinases. Kidney Int. 1993, 44:1266-1272.
190. Prontera C., Mariani B., Rossi C., Poggi A., Rotilio D. Inhibition of gelatinase A (MMP-2) by batimastat and captopril reduces tumor growth and lung metastases in mice bearing Lewis lung carcinoma. Int. J. Cancer. J. Int. du Cancer 1999, 81:761-766.
191. Nakagawa T., Kubota T., Kabuto M., Kodera T. Captopril inhibits glioma cell invasion in vitro: involvement of matrix metalloproteinases. Anticancer Res. 1995, 15:1985-1989.
192. Small W., Molteni A., Kim Y.T., Taylor J.M., Ts'ao C.H., Ward W.F. Mechanism of captopril toxicity to a human mammary ductal carcinoma cell line in the presence of copper. Breast Cancer Res. Treat. 1999, 55:223-229.
193. Miyajima A., Asano T., Hayakawa M. Captopril restores transforming growth factor-beta type II receptor and sensitivity to transforming growth factor-beta in murine renal cell cancer cells. J. Urol. 2001, 165:616-620.
194. Nittler T., Stone M., Shroff D., McArthur C., Veno P., Dobbs L., Brizio-Molteni L., Molteni A. Inhibitory effect of captopril on proliferation of a human salivary gland adenocarcinoma cell line. FASEB J. 1998, 12:4702.
195. Ward W.F., Molteni A., Ts'ao C., Hinz J.M. The effect of Captopril on benign and malignant reactions in irradiated rat skin. Br. J. Radiol. 1990, 63:349-354.
196. Vogt B., Frey F.J. Inhibition of angiogenesis in Kaposi's sarcoma by captopril. Lancet 1997, 349:1148.
197. Furuta S., Ortiz F., Zhu Sun X., Wu H.H., Mason A., Momand J. Copper uptake is required for pyrrolidine dithiocarbamate-mediated oxidation and protein level increase of p53 in cells. Biochem. J. 2002, 365:639-648.
198. Burkitt M.J., Bishop H.S., Milne L., Tsang S.Y., Provan G.J., Nobel C.S., Orrenius S., Slater A.F. Dithiocarbamate toxicity toward thymocytes involves their copper-catalyzed conversion to thiuram disulfides, which oxidize glutathione in a redox cycle without the release of reactive oxygen species. Arch. Biochem. Biophys. 1998, 353:73-84.
199. Tsai J.C., Jain M., Hsieh C.M., Lee W.S., Yoshizumi M., Patterson C., Perrella M.A., Cooke C., Wang H., Haber E., Schlegel R., Lee M.E. Induction of apoptosis by pyrrolidinedithiocarbamate and N-acetylcysteine in vascular smooth muscle cells. J. Biol. Chem. 1996, 271:3667-3670.
200. Daniel K.G., Chen D., Orlu S., Cui Q.C., Miller F.R., Dou Q.P. Clioquinol and pyrrolidine dithiocarbamate complex with copper to form proteasome inhibitors and apoptosis inducers in human breast cancer cells. Breast Cancer Res. 2005, 7:R897-908.
201. Daniel K.G., Gupta P., Harbach R.H., Guida W.C., Dou Q.P. Organic copper complexes as a new class of proteasome inhibitors and apoptosis inducers in human cancer cells. Biochem. Pharmacol. 2004, 67:1139-1151.
202. Vallari R.C., Pietruszko R. Human aldehyde dehydrogenase: mechanism of inhibition of disulfiram. Science 1982, 216:637-639.
203. Hald J., Jacobsen E. A drug sensitizing the organism to ethyl alcohol. Lancet 1948, 2:1001-1004.
204. Chen D., Cui Q.C., Yang H., Dou Q.P. Disulfiram, a clinically used anti-alcoholism drug and copper-binding agent, induces apoptotic cell death in breast cancer cultures and xenografts via inhibition of the proteasome activity. Cancer Res. 2006, 66:10425-10433.
205. Conticello C., Martinetti D., Adamo L., Buccheri S., Giuffrida R., Parrinello N., Lombardo L., Anastasi G., Amato G., Cavalli M., Chiarenza A., De Maria R., Giustolisi R., Gulisano M., Di Raimondo F. Disulfiram, an old drug with new potential therapeutic uses for human hematological malignancies. Int. J. Cancer 2012, 131:2197-2203.
206. Rahden-Staron I., Grosicka-Maciag E., Kurpios-Piec D., Czeczot H., Grzela T., Szumilo M. The effects of sodium diethyldithiocarbamate in fibroblasts V79 cells in relation to cytotoxicity, antioxidative enzymes, glutathione, and apoptosis. Arch. Toxicol. 2012, 86:1841-1850.
207. Jatoe S.D., Lauriault V., McGirr L.G., O'Brien P.J. The toxicity of disulphides to isolated hepatocytes and mitochondria. Drug Metabol. Drug Interact. 1988, 6:395-412.
208. Loo T.W., Clarke D.M. Blockage of drug resistance in vitro by disulfiram, a drug used to treat alcoholism. J. Natl Cancer Inst. 2000, 92:898-902.
209. Freskos J.N., McDonald J.J., Mischke B.V., Mullins P.B., Shieh H.S., Stegeman R.A., Stevens A.M. Synthesis and identification of conformationally constrained selective MMP inhibitors. Biorg. Med. Chem. Lett. 1999, 9:1757-1760.
210. Hayashi R., Jin X., Cook G.R. Synthesis and evaluation of novel heterocyclic MMP inhibitors. Biorg. Med. Chem. Lett. 2007, 17:6864-6870.
211. Hurst D.R., Schwartz M.A., Jin Y., Ghaffari M.A., Kozarekar P., Cao J., Sang Q.X. Inhibition of enzyme activity of and cell-mediated substrate cleavage by membrane type 1 matrix metalloproteinase by newly developed mercaptosulphide inhibitors. Biochem. J. 2005, 392:527-536.
212. Park H.I., Jin Y., Hurst D.R., Monroe C.A., Lee S., Schwartz M.A., Sang Q.X. The intermediate S1' pocket of the endometase/matrilysin-2 active site revealed by enzyme inhibition kinetic studies, protein sequence analyses, and homology modeling. J. Biol. Chem. 2003, 278:51646-51653.
213. Baxter A.D., Bhogal R., Bird J.B., Buckley G.M., Gregory D.S., Hedger P.C., Manallack D.T., Massil T., Minton K.J., Montana J.G., Neidle S., Owen D.A., Watson R.J. Mercaptoacyl matrix metalloproteinase inhibitors: the effect of substitution at the mercaptoacyl moiety. Biorg. Med. Chem. Lett. 1997, 7:2765-2770.